This article provides a comprehensive, up-to-date review of methods to prevent early and
late renal-allograft loss and to improve long-term outcomes in patients. The authors focus …

Effective immunosuppression is an essential pre-requisite for successful organ
transplantation and improvements in outcome after transplantation have to a large extent …

Background There are few comparisons of antibody induction therapy allowing early
glucocorticoid withdrawal in renal-transplant recipients. The purpose of the present study …

Background Steroid‐sparing strategies have been attempted in recent decades to avoid
morbidity from long‐term steroid intake among kidney transplant recipients. Previous …

T-cell depletion facilitates reduced immunosuppression following organ transplantation and
has been suggested to be pro-tolerant. However, the characteristics of post-depletional T …

Background Prolonging kidney transplant survival is an important clinical priority. Induction
immunosuppression with antibody therapy is recommended at transplantation and non …

Campath‐1H, an anti‐CD52 monoclonal antibody, was used as induction therapy (40 mg iv
total dose) in 29 primary human renal transplants, and the patients were maintained on …

Since the initial reporting of the successful reversal of hyperglycemia through the
transplantation of pancreatic islets, significant research efforts have been conducted in …

Background. Alemtuzumab is an emerging therapy for refractory lymphoproliferative
disorders. The associated long-term risks of infection remain poorly defined. Methods. From …

Background. Alemtuzumab is being increasingly used for the prevention and/or treatment of
acute allograft rejection in organ transplant recipients. We assessed the risks of infection in …